Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. (Q38905340)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. |
scientific article |
Statements
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus (English)
Huai-Xiang Hao
David Chen
Richard Ong
Khee Chee Soo
Panisa Pochanard
David Yang
David Ruddy
Manway Liu
Adnan Derti
Marissa N Balak
Michael R Palmer
Yan Wang
Benjamin H Lee
Dalila Sellami
Andrew X Zhu
Robert Schlegel
1 reference
1 reference